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Fatty acids are the primary fuel source for skeletal
muscle during most of our daily activities, and
impaired fatty acid oxidation (FAO) is associated
with insulin resistance. We have developed a mouse
model of impaired FAO by deleting carnitine pal-
mitoyltransferase-1b specifically in skeletal mus-
cle (Cpt1bm/). Cpt1bm/ mice have increased
glucose utilization and are resistant to diet-induced
obesity. Here, we show that inhibition of mitochon-
drial FAO induces FGF21 expression specifically in
skeletal muscle. The induction of FGF21 in Cpt1b-
deficient muscle is dependent on AMPK and Akt1
signaling but independent of the stress signaling
pathways. FGF21 appears to act in a paracrine
manner to increase glucose uptake under low insulin
conditions, but it does not contribute to the resis-
tance to diet-induced obesity.INTRODUCTION
Fat contributes 90% of the substrate for resting energy expendi-
ture in skeletal muscle and remains the primary fuel during daily
activities and low exercise intensities (<40% VO2 max) (Brooks,
1997; Brooks and Mercier, 1994; Dagenais et al., 1976; Kelley
et al., 1993). Carnitine palmitoyltransferase-1 (CPT1) is located
on the outer mitochondrial membrane and transports long-chain
fatty acids intomitochondria for b-oxidation.We created amouse
model of impaired fatty acid oxidation (FAO) by deleting CPT1b in
skeletal muscle (Cpt1bm/) and reported that inhibition of mito-
chondrial FAO leads to activation of AMPK and PGC1a, resulting
in adaptivemetabolic responses in skeletalmusclewith increased
mitochondrial biogenesis, oxidative capacity, compensatory
peroxisomal fat oxidation, and amino acid catabolism (Wicks1686 Cell Reports 15, 1686–1699, May 24, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://et al., 2015). In addition, despite elevated plasma lipids and accu-
mulationofboth intramyocellular lipidsand lipotoxic species, fast-
ing insulin and glucose are lower in Cpt1bm/ mice, with
enhanced glucose utilization in Cpt1bm/ mice. Here we report
what appears to be a local starvation response in which FGF21
is specifically upregulated in skeletal muscle of Cpt1bm/mice.
FGF21 was identified as a novel member of the FGF family that
is highly expressed in liver (Nishimura et al., 2000). FGF21 was
subsequently shown to be a potent metabolic regulator of
glucose uptake in adipocytes (Kharitonenkov et al., 2005) and
is generally thought of as a secreted protein produced by liver
in response to starvation (Badman et al., 2007; Inagaki et al.,
2007). However, under myopathic conditions resulting from
deficiencies in the mitochondrial respiratory chain, FGF21 can
be secreted from skeletal muscle (Kim et al., 2013b; Tyynismaa
et al., 2010). In addition, the transgenic overexpression of Akt1
(Izumiya et al., 2008), perilipin 5 (Harris et al., 2015), and UCP1
(Keipert et al., 2014; Ost et al., 2015) in skeletal muscle induces
FGF21 secretion. The skeletal muscle-specific ablation of auto-
phagy-related 7 leads to an autophagy deficiency andmitochon-
drial dysfunction and increases FGF21 in muscle (Kim et al.,
2013b; Tyynismaa et al., 2010). In addition, the skeletal mus-
cle-specific ablation of tuberous sclerosis complex (Tsc) 1,
causing activation of mTORC1, induces FGF21 secretion from
muscle (Guridi et al., 2015). A common link among these mouse
models (except Akt1 overexpression) is metabolic dysfunction,
endoplasmic reticulum (ER) stress, and activation of activating
transcription factor 4 (Atf4) as a master regulator of the integra-
tive stress response leading to FGF21 induction.
In the present study, we address whether upregulation of
FGF21 in skeletal muscle contributes to the enhanced carbo-
hydrate metabolism (improved insulin sensitivity and glucose
utilization) in response to inhibition of mitochondrial FAO in
Cpt1bm/ mice. We demonstrate that FGF21 can be upregu-
lated by restricting FAO in muscle in an AMPK-Akt1-dependent
manner without activation of the integrative stress response. We
also determine the role of FGF21 in the overall phenotype of)
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Muscle-Derived FGF21 Enhances
Glucose Uptake in Skeletal Muscle in
Cpt1bm/ Mice
(A) Serum FGF21 concentration in 4-month-old
Cpt1bm/ and Cpt1bfl/fl mice fed and fasted
overnight (n = 7–9 per group).
(B) Fgf21 gene expression in muscle tissue such
as gastrocnemius (Gastroc), soleus, extensor dig-
itorum longus (EDL), white and red quads (W.Quad
andR.Quad), and other tissue, such as liver, eWAT,
and iWAT, from 3- to 5-month-old Cpt1bm/ and
Cpt1bfl/fl mice (n = 5–8).
(C) Immunoblot analysis showing bKlotho and
Glut1 protein abundance in gastrocnemius muscle
from 4-month-old Cpt1bm/ and Cpt1bfl/fl mice.
GAPDH was used as a loading control. ImageJ
software was used for densitometry quantification
of the immunoblots. Results shown are represen-
tative of three separate experiments (n = 3–4 per
group).
(D) Fgf21 gene expression primary myotubes es-
tablished from Cpt1bm/ and Cpt1bfl/fl mice.
(E) Secreted FGF21 over 24 hr in culture media
from primary myotubes initiated from Cpt1bm/
and Cpt1bfl/fl mice.
(F) Basal and insulin-stimulated [3H]-2-deoxy-
glucose uptake in primary myotubes from
Cpt1bm/ and Cpt1bfl/fl mice.
(G) Primary myotubes from Cpt1bm/ and
Cpt1bfl/fl mice (3–5 months of age) were pre-
treated with vehicle (PBS) or rmFGF21 (250 ng/ml,
16 hr), and then [3H]-2-deoxyglucose uptake was
measured. Results shown are representative of
four independent experiments.
All data are presented as mean ± SEM. *p < 0.05
and **p < 0.01 between Cpt1bm/ and Cpt1bfl/fl
mice, and #p < 0.05 between vehicle and insulin or
rmFGF21 treatments.Cpt1bm/ mice using CPT1b and FGF21 double knockout
mice (DKO).
RESULTS
Mitochondrial FAO Deficiency in Muscle Induces FGF21
Serum FGF21 levels were significantly higher in both fed and
fasted states in Cpt1bm/ mice compared to control mice
(Figure 1A). To determinewhether increased FGF21 in circulation
was arising partly from skeletal muscle, we examined Fgf21 gene
expression in several tissues. The mRNA expression of Fgf21
was markedly upregulated in several muscles of Cpt1bm/
mice compared to Cpt1bfl/fl mice, without changes in liver or
white adipose tissue (WAT) (Figure 1B).
We next evaluated the effect of muscle-specific upregulation
of FGF21 on glucose uptake in skeletal muscle. Gene expression
of Fgfr1 and its spliced variants Fgfr1b and Fgfr1c were not
different in skeletal muscle between Cpt1bm/ and control
mice (Figures S1A–S1C). However, proteomic (Wicks et al.,
2015) and immunoblot analyses of muscle from Cpt1bm/
mice revealed significantly elevated protein expression of b-Klo-
tho in muscle, which is the essential co-receptor for FGF21 (Fig-
ure 1C) (Ogawa et al., 2007). Consistent with reports that FGF21increases glucose uptake via glucose transporter 1 (Glut1) (Khar-
itonenkov et al., 2005; Mashili et al., 2011), protein expression of
Glut1 was markedly increased in muscle of Cpt1bm/ mice
compared to controls (Figure 1C).
Primarymyotubes fromCpt1bm/micehaveametabolic gene
expression profile similar to that in muscle from Cpt1bm/ mice
(Figures S1D and S1E). We found significantly increased mRNA
expression and protein secretion of FGF21 in primary myotubes
derived fromCpt1bm/micecompared toCpt1bfl/flmice (Figures
1D and 1E). Basal glucose uptake was significantly elevated in
primary myotubes fromCpt1bm/mice; however, insulin-stimu-
lated glucose uptake was comparable to Cpt1bfl/fl mice (Fig-
ure 1F). FGF21 treatment significantly increased glucose uptake
in myotubes from both Cpt1bm/ and control mice, suggesting
the elevated basal glucose uptake in myotubes from Cpt1bm/
mice is potentially a result from enhanced FGF21 production
(Figure 1G).
Insulin Sensitivity in Cpt1b-Deficient Muscle Is
Maintained through mTOR-Akt Signaling
To determine the underlyingmolecular mechanisms of increased
glucose utilization despite lipotoxity in Cpt1bm/ mice, we first
examined the mTOR signaling pathway, which senses nutrientCell Reports 15, 1686–1699, May 24, 2016 1687
Figure 2. mTOR-Akt Signaling Pathways Are Involved in Induction of Fgf21 in an Energy-Deficient Condition Caused by Impaired
Mitochondrial FAO
(A and B) Activity ofmTOR (A) and downstreammembers of themTORC1 signaling pathway, P70S6K and IRS1 (B), in gastrocnemiusmuscle fromCpt1bm/ and
Cpt1bfl/fl mice.
(C) Akt and IR signaling at baseline in gastrocnemius muscle from Cpt1bm/ and Cpt1bfl/fl mice.
(D) Gene expression of Akt signaling members, Akt1, Akt2, and Akt3 in gastrocnemius muscle from Cpt1bm/ and Cpt1bfl/fl mice (n = 8).
(E and F) Immunoblot analysis of basal and insulin-stimulated Akt1 (E) and Akt2 (F) signaling by phosphorylation at Ser473 and Ser 474, respectively, in red quad
muscle from Cpt1bm/ and Cpt1bfl/fl mice. GAPDH was used as a loading control. ImageJ software was used for densitometry quantification of the immu-
noblots.
(G) Activation of TSC2, as examined by phosphorylation at Ser1387 and Thr1462, in red quad muscle from Cpt1bm/ and Cpt1bfl/fl mice. Results shown are
representative of three independent experiments (n = 4 per group).
(H) Proposed model explaining mechanisms of interplay of the AMPK, mTOR, and Akt signaling pathways in the FGF21 induction and enhanced glucose
utilization in the condition with mitochondrial FAO deficiency.
All data are presented as mean ± SEM. *p < 0.05 and **p < 0.01.and energy levels and integrates upstream and downstream sig-
nals, including growth factors such as insulin (Wullschleger et al.,
2006). Phosphorylation of mTOR at Ser2448, the site associated
with mTORC1 activity (Chiang and Abraham, 2005), was signif-
icantly decreased in muscle of Cpt1bm/ mice compared to
Cpt1bfl/fl mice (Figure 2A). Likewise, phosphorylation of P70 iso-
form of S6K1, the main downstream effector of mTORC1 (Wulls-
chleger et al., 2006), was significantly reduced in skeletal muscle
from Cpt1bm/ mice (Figure 2B). Activation of mTORC1 nega-
tively regulates insulin sensitivity via activation of S6K1, which
inhibits IRS protein responsiveness to insulin stimulation by
directly phosphorylating IRS1 at Ser636/639 (Um et al., 2004;
Wullschleger et al., 2006). In Cpt1bm/ skeletal muscle, serine
phosphorylation of IRS1 was significantly decreased, suggest-
ing reduced mTORC1 signaling (Figure 2B). In addition, tyrosine1688 Cell Reports 15, 1686–1699, May 24, 2016phosphorylation of IRS1, which facilitates insulin responsiveness
(Copps and White, 2012), is significantly increased in skeletal
muscle of Cpt1bm/ mice compared to control mice (Fig-
ure S2A). As a consequence of decreased inhibitory action of
mTORC1 signaling in Cpt1bm/ muscle in the basal state, we
detected significant reductions in basal phosphorylation of
both Akt (Ser473) and insulin receptor (IR) (Tyr1162/1163) in
skeletal muscle using multiplex and immunoblot analysis (Fig-
ures 2C and S2B). Based upon this evidence we predicted that
reduced mTORC1 signaling in the basal state would not only
improve basal glucose clearance but also increase sensitivity
of Cpt1bm/ muscle to insulin stimulation. Consistent with
this, fasting plasma insulin levels were decreased in Cpt1bm/
mice and remained significantly lower throughout life (Wicks
et al., 2015). However, insulin-stimulated phosphorylation of
total Akt (Ser473) was comparable betweenCpt1bm/ and con-
trol mice (Wicks et al., 2015).
The Akt family includes three members: (1) Akt1 is involved in
cellular survival pathways (Chen et al., 2001), and gene levels
were elevated in muscle of Cpt1bm/mice; (2) Akt2 is an impor-
tant molecule in the insulin signaling pathway (Garofalo et al.,
2003), but mRNA expression was not different between geno-
types; and (3) Akt3 was undetectable in skeletal muscle (Fig-
ure 2D). Phosphorylation of Akt1 (Ser473) at baseline was not
different betweengenotypes, but insulin-stimulated phosphoryla-
tionwassignificantly greater in skeletalmuscleofCpt1bm/mice
(Figure 2E). Phosphorylation of Akt2 (Ser474) at baseline was
significantly decreased in muscle of Cpt1bm/ mice compared
to Cpt1bfl/fl mice, whereas insulin-stimulated Akt2 phosphoryla-
tion was comparable between genotypes (Figure 2F).
To gain further insight into how impaired mitochondrial FAO
causes inhibition of mTORC1 signaling, we next examined
upstream factors that affect the mTORC1 pathway. TSC1/TSC2
is a critical regulator of mTOR signaling, and activation of this
complex inhibits mTORC1 (Wullschleger et al., 2006). In contrast,
TSC1/TSC2 activates mTORC2, which in turn triggers Akt1 acti-
vation (Huang and Manning, 2009). Within the TSC1/TSC2 com-
plex, TSC1 stabilizes TSC2 (Chong-Kopera et al., 2006), which
facilitates activation of TSC2 by kinases such as AMPK and Akt
that directly phosphorylate TSC2 at Ser1387 (Inoki et al., 2003)
and Thr1462 (Huang andManning, 2008), respectively. We found
significantly elevatedphosphorylationof TSC2atSer1387 inmus-
cle of Cpt1bm/ mice, whereas phosphorylation of TSC2 at
Thr1462 was not different. These findings suggest TSC2 activa-
tionoccurs viaAMPKbutnotAkt inCpt1bm/muscle (Figure2G).
This is consistent with our previous report that mitochondrial FAO
deficiency induced a low-energy state in skeletal muscle of
Cpt1bm/ mice that activated AMPK (Wicks et al., 2015) but
extends these findings by suggesting that AMPK stimulates
the TSC1/TSC2 complex in Cpt1bm/ mice (Figure 2H). Specif-
ically, these findings suggest that TSC1/TSC2 inhibits mTORC1
signaling, resulting in enhanced basal insulin sensitivity, and acti-
vates the mTORC2 pathway in Cpt1bm/mice, which increases
basal glucose uptake (Figure 2H).
Fgf21 Induction in Cpt1b-Deficient Muscle Is AMPK and
Akt1 Dependent
Within the model shown in Figure 2H, we predict AMPK and Akt1
signaling are necessary for induction of FGF21 in skeletal muscle
of Cpt1bm/mice. To test this directly, we used mouse and hu-
man primarymuscle cells. In agreement with ourmechanistic hy-
pothesis (Figure 2H), expression of Fgf21 in primary myotubes
from Cpt1bm/ mice was normalized when exposed to either
an Akt1-specific inhibitor, A-674563, or an AMPK inhibitor, com-
pound C (Figure 3A). To test whether pharmacological inhibition
of CPT1b recapitulates effects of genetic inhibition of Cpt1b, we
exposed primary myotubes from Cpt1bfl/fl mice to fatty acid (FA)
in the presence of the CPT1 inhibitor, etomoxir. Fgf21 expression
was not induced in the presence of FA alone but was robustly
elevated in myotubes exposed to FA in the presence of etomoxir
in a dose-dependent manner (Figures 3B and S2C).
To study whether the pharmacological inhibition of CPT1
drives FGF21 induction in the insulin-resistant condition, weexplored human skeletal muscle myotubes from diabetic-obese
subjects. Our previous report demonstrated that these myo-
tubes are insulin-resistant compared to myotubes derived from
non-diabetic-lean (normal-lean) humans (Vandanmagsar et al.,
2014). Treatment with FA induced FGF21 expression in the pres-
ence of etomoxir in myotubes from both normal-lean and dia-
betic-obese subjects; however, FGF21 induction was blunted
in myotubes from diabetic-obese subjects (Figure 3C). Exposure
to A-674563 and compound C blunted FA + etomoxir induction
of FGF21 in myotubes from both groups (Ferre´, 2004). FGF21
is induced by PPARa in liver in response to fasting (Inagaki
et al., 2007). However, treatment with inhibitors of PPARa,
PPARg, and PPARd did not affect FA + etomoxir-induced
FGF21 expression in myotubes from normal-lean subjects (Fig-
ure 3D). Collectively, these data indicate involvement of AMPK
and Akt1 signaling in FGF21 induction in the mitochondrial
FAO-deficient condition.
To test whether FGF21 directly imparts beneficial effects on the
insulin signaling cascade in thepresenceof excessFA,we treated
human myotubes from normal-lean subjects with rhFGF21 ± FA
and determined activity of mTOR and its downstream signaling
pathways. In the absence of FA, FGF21 had minimal effects,
because only phosphorylation of p70S6K was reduced. Alterna-
tively,whenFAwaspresent,FGF21wasable to reducephosphor-
ylation of mTor (Ser2448), p70S6K, IRS1 (Ser636/639), and Akt
(Ser473) (Figure 3E). Taken together, these data suggest that
FGF21 has protective effects on lipid-induced insulin resistance,
which in turn preserves glucose uptake inmuscle in lipotoxic con-
ditions, such as in skeletal muscle of Cpt1bm/mice.
Stress Signaling Pathways Are Not Activated by
Mitochondrial Fat Oxidation Deficiency
To determine whether other potential signaling pathways lead to
induction of FGF21 in skeletal muscle of Cpt1bm/ mice, we
evaluated other mechanisms linked to mTOR signaling and
FGF21 induction. In Cpt1bm/mice, systemic and intramyocel-
lular lipids, particularly toxic diacylglycerol (DAG) species, are
increased (Wicks et al., 2015); thus, DAG signaling could be
enhanced. Previous reports have shown that DAG kinases inhibit
mTOR activation by repressing Erk1/2 pathways (Gorentla et al.,
2011). Erk1/2 directly phosphorylates TSC2, thus negatively
regulating mTORC1 signaling (Ma et al., 2005; Wullschleger
et al., 2006). Phosphorylation of Erk1/2 was not elevated in skel-
etal muscle of Cpt1bm/mice (Figure 4A). In addition, oxidative
stress and hypoxia have been linked to mTORC1 activity (Kim
et al., 2002; Wouters and Koritzinsky, 2008). Gene expression
of oxidative stress (Nrf2) and hypoxia (Hif1a) markers was not
elevated in muscle of Cpt1bm/ mice compared to Cpt1bfl/fl
mice (Figures 4B and 4C). Furthermore, the expression levels
of ER stress markers (unspliced Xbp1u and spliced Xbp1s)
were unchanged in Cpt1bm/ muscle (Figure 4D). Moreover,
ER stress marker Ddit3 (Haynes and Ron, 2010) expression
was significantly decreased in Cpt1bm/ muscle (Figure 4E).
In line with these data, Atf4 mRNA and protein expression and
Atf5 mRNA expression in skeletal muscle were similar between
Cpt1bm/ and Cpt1bfl/fl mice (Figures 4F and S2D).
In addition to the candidate gene approach, we did a compre-
hensive global expression analysis in gastrocnemius muscleCell Reports 15, 1686–1699, May 24, 2016 1689
Figure 3. Fgf21 Induction in Skeletal Muscle
of Cpt1bm/ Mice Is AMPK and Akt1
Dependent
(A and B) Gene expression of Fgf21 in mouse
primary myotubes treated with an Akt1 inhibitor,
A-674563 (30 mM), and an AMPK inhibitor, com-
pound C (CompC, 30 mM), for 24 hr. (A) Results
shown are representative of three independent
cultures. *p < 0.05 between Cpt1bm/ and
Cpt1bfl/fl mice, and #p < 0.05 between treatments
with vehicle and inhibitors. (B) Primary muscle cells
from Cpt1bfl/fl mice. Myotubes were treated with
BSA-conjugated FA (FA, 0.5 mM) in the presence
of the Cpt1 inhibitor etomoxir (Et, 100 mM) for 24 hr.
Results shown are representative of three or four
separate experiments. *p < 0.05 between control
(BSA) and other treatments, and #p < 0.05 due to
Akt1 or AMPK inhibitors.
(C) Gene expression of FGF21 in human myotubes
treated with FA (0.5 mM) and inhibitors Et (100 mM),
A-674563 (50 mM), and CompC (30 mM) for 24 hr.
HSMMs derived from normal-lean and diabetic-
obese subjects were differentiated into myotubes
before treatments (n = 4 per group). Results shown
are representative of two independent cultures of
HSMM per subject. *p < 0.05 between treatments
with FA and inhibitors, #p < 0.05 due to Akt1 or
AMPK inhibitors, and &p < 0.05 between myotubes
from normal-lean and diabetic-obese subjects.
(D) Gene expression of FGF21 in human myotubes
treatedwith FA (0.5mM) and Et (100 mM) and PPAR
inhibitors GW6471 (for PPARa, 10 mM), T0070907
(for PPARg, 10 mM), and GSK3787 (for PPARd,
10 mM) for 24 hr. *p < 0.05 between treatments with
inhibitors and BSA control.
(E) Activity of mTORC1 and its downstream signaling members P70S6K, IRS1, and basal Akt, as determined by phosphorylation in human myotubes. HSMMs
originating from normal-lean subjects were differentiated into myotubes before treatment with FA (0.5 mM) and rhFGF21 (200 ng/ml). *p < 0.05 between vehicle
(PBS) and other treatments.
All data are presented as mean ± SEM.from Cpt1bm/ and control mice. The genes belonging to ER
stress, autophagy, and mitophagy pathways were obtained
from gene ontology and then compared by pathway enrichment
analysis by including these three pathways to the standard Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways. None
of these overall pathways were significantly different between
Cpt1bm/ and Cpt1bfl/fl mice (Figure 4G). At the gene level,
only 1 gene (Ppp1r15a) out of more than 200 genes was signifi-
cantly different betweenCpt1bm/ and control mice. Heatmaps
showing the distribution of expression for genes belonging to
these pathways are included in Supplemental Information (Fig-
ures S3–S5). Moreover, uncoupling protein 3 (Ucp3) expression
was significantly increased in Cpt1bm/ muscle (Figure 4H),
suggesting potential beneficial effects, because it has been re-
ported that upregulated expression of UCP3 reduced ER stress
(Xu et al., 2015) and reactive oxygen species (ROS) production
(Nabben et al., 2011). Together, these data indicate that mito-
chondrial respiratory chain dysfunction and myocellular stress
do not appear to be major inducers of FGF21 inCpt1bm/mus-
cle and are consistent with our previous report that Cpt1b-defi-
cient mitochondria respire efficiently when given substrates
other than long-chain fatty acids (Wicks et al., 2015). Pathways
for oxidative phosphorylation, tricarboxylic acid (TCA) cycle,1690 Cell Reports 15, 1686–1699, May 24, 2016and overall mitochondrial biogenesis are upregulated in
Cpt1bm/ muscle (Wicks et al., 2015).
Loss of FGF21 Increases Muscle Mass, Activity, Energy
Expenditure, and Oxidative Capacity but Does Not Alter
Adiposity in Cpt1bm/ Mice
Todetermine theextent ofFGF21’s role in theoverall phenotypeof
Cpt1bm/ mice, we generated DKO mice (Fgf21/Cpt1bm/)
by crossing Fgf21/ mice (Badman et al., 2009; Hotta et al.,
2009) with Cpt1bm/ mice. As shown in Figure 5A, there was
an intermediate effect on body weight in DKO mice. DKO mice
were significantly heavier than Cpt1bm/mice but did not reach
the bodyweight of control or Fgf21/mice (Figure 5A). However,
there was no difference in fat mass between Cpt1bm/ and
DKO mice, as measured by nuclear magnetic resonance (NMR)
(Figure 5B) or by the weight from individual fat pads (Figure
5D). Fat-free mass (FFM) was significantly increased in DKO
compared to Cpt1bm/ mice (Figure 5C). Gastrocnemius and
quadriceps muscles were heavier in both DKO and Fgf21/
mice, but liver, kidney, and heart weights were not significantly
higher in DKO compared to Cpt1bm/ mice (Figure 5D). Body
length was significantly decreased in both Cpt1bm/ and DKO
micecompared tocontrolmice,whereasFgf21/miceappeared
Figure 4. Stress Signaling Pathways that Are Not Activated by Mitochondrial Fat Oxidation Deficiency
(A) Activity of Erk1/2 signaling pathway, as determined by multiplex protein signaling assay (left) and western blot analysis (center) for phosphorylation in
gastrocnemius muscle from 4-month-old Cpt1bm/ and Cpt1bfl/fl mice (n = 3–4 per group). The Thr185/Tyr187 antibody detects phosphorylation at Thr185 and
Tyr187. GAPDH was used as a loading control. ImageJ software was used for densitometry quantification of the immunoblots (right).
(B and C) Gene expression of oxidative stress (B) and hypoxia (C) markers, as examined by qRT-PCR in muscle.
(D and E) ER stress markers in muscle. Gene expression of unspliced and spliced Xbp1 (D) and Ddit3 (E), as determined by qRT-PCR in muscle tissue
(F) Gene and protein expression of Atf4, as detected by qRT-PCR and western blot, respectively, in skeletal muscle.
(G) Summary of results from gene expression and pathway analysis for ER stress, autophagy, and mitophagy using gene ontology and pathway enrichment
analysis on SAGE (serial analysis of gene expression) data obtained from gastrocnemius muscle.
(H) Gene expression of uncoupled protein 3 (Ucp3), as evaluated by qRT-PCR in skeletal muscle. Gene expression analysis was performed in muscle tissue such
as soleus (Sol), extensor digitorum longus (EDL), white and red quads (W.Q. and R.Q.), and gastrocnemius from 4-month-old Cpt1bm/ and Cpt1bfl/fl mice
(n = 6–8 per group). Immunoblot analysis was performed in gastrocnemius muscle from 4-month-old Cpt1bm/ and Cpt1bfl/fl mice. Results shown are
representative of three independent experiments (n = 4–6 per group).
All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.005 and higher significance.
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Figure 5. Loss of FGF21 Increases Muscle Mass, Activity, Energy Expenditure, and Oxidative Capacity but Does Not Alter Adiposity in
Cpt1bm/ Mice
(A–C) Body weight (A), fat mass (B), and FFM (C) (n = 7 per group).
(D) Tissue weights (n = 7).
(E) Body length (n = 8–14).
(F) Energy expenditure, activity level, and RER (n = 4–6 per group).
(G–I) Substrate oxidation measured in gastrocnemius muscle homogenate from control (Fgf21+/+Cpt1bfl/fl),Cpt1bm/ (Fgf21+/+Cpt1bm/), Fgf21/ (Fgf21/
Cpt1bfl/fl), and DKO (Fgf21/Cpt1bm/) mice: (G) peroxisomal FAOmeasured from [1-14C]lignoceric acid (20 mM), (H) PDHactivity assayedwith [1-14C]pyruvate
and pyruvate oxidation measured with [3-14C]pyruvate, and (I) leucine oxidation measured from [U-14C]leucine (100 mM) (n = 8–12 per group).
All data are presented as mean ± SEM. (A–C) *p < 0.05 significance when Cpt1bm/mice were compared to control and DKO mice. (D–I) *p < 0.05 significance
compared to control mice, #p < 0.05 significance compared to Fgf21/ mice, and &p < 0.05 significance compared to Cpt1bm/ mice.to have body length significantly longer than that of Cpt1bm/
andDKOmice (Figure 5E).Cpt1bm/micehave reducedactivity,
leading to an overall decrease in energy expenditure (Figure 5F)
(Wicks et al., 2015). The decreased activity in Cpt1bm/ mice is
almost restoredby the lack of FGF21 inDKOmicewith a concom-
itant increase in energy expenditure (Figure 5F). In addition, the
respiratory exchange ratio (RER) in DKO mice was comparable
to that in control mice (Figure 5F).
As we previously reported, inhibition of mitochondrial FAO
specifically in skeletal muscle results in favorable metabolic ad-
aptations in muscle, such as compensatory increases in carbo-
hydrate oxidation, amino acid oxidation, and peroxisomal fat
oxidation (Wicks et al., 2015). Likewise, we observed increased
peroxisomal oxidation of the very long-chain fatty acid lignocer-1692 Cell Reports 15, 1686–1699, May 24, 2016ate (Figure 5G), enhanced pyruvate dehydrogenase (PDH) activ-
ity and pyruvate oxidation through the TCA cycle (Figure 5H),
and leucine oxidation in skeletal muscle homogenates from
Cpt1bm/mice compared to those from controlmice (Figure 5I).
The expression of mitochondrial biogenesis genes in muscle
of DKO was comparable to the increased level in Cpt1bm/
muscle (Figure S6A). Loss of FGF21 had little effect on oxida-
tion, but the combined loss of CPT1b and FGF21 in DKO mice
further increased PDH activity and increased pyruvate oxidation
through the TCA cycle, leucine oxidation, and peroxisomal
oxidation (Figures 5G–5I). In summary, overall fat mass is not
increased in DKO mice. Rather, elevated FGF21 in Cpt1bm/
mice seems to negatively regulate muscle mass, activity, and
energy expenditure.
Figure 6. FGF21 Is Responsible for Increased Glucose Utilization in Cpt1bm/ Muscle
(A and B) GTT (A; n = 14–22 per group) and ITT (B; n = 7–11 per group).
(C–H) Immunoblot analysis of Akt proteins. Basal (C) and insulin-stimulated (D) phosphorylation of total Akt at Ser473. Basal (E) and insulin-stimulated (F)
phosphorylation of Akt1 at Ser473. Basal (G) and insulin-stimulated (H) phosphorylation of Akt2 at Ser474. GAPDH was used as a loading control. Results shown
are representative of three independent experiments. Gastrocnemius muscle from control (Fgf21+/+ Cpt1bfl/fl), Cpt1bm/ (Fgf21+/+ Cpt1bm/), Fgf21/
(Fgf21/Cpt1bfl/fl), and DKO (Fgf21/Cpt1bm/) mice were used for all immunoblot analyses (n = 3–5 per group). ImageJ software was used for densitometry
quantification of the immunoblots.
All data are presented as mean ± SEM. (A and B) *p < 0.05 significance between control and Cpt1bm/ mice, #p < 0.05 significance between Cpt1bm/ and
Fgf21/ mice, and &p < 0.05 significance between Cpt1bm/ and DKO mice. (C–H) *p < 0.05 significance compared to control mice, #p < 0.05 significance
compared to Fgf21/ mice, and &p < 0.05 significance compared to Cpt1bm/ mice.Glucose Utilization and Insulin Signaling Are Partially
Regulated by FGF21 in Cpt1bm/ Mice
Blood glucose levels are significantly decreased in Cpt1bm/
mice compared to control (Cpt1bfl/fl) mice during a glucose toler-
ance test (GTT), indicating improved glucose clearance. This
improvement was partially negated in DKO mice compared to
Cpt1bm/ mice (Figure 6A). Compared to control mice,
insulin-stimulated glucose clearance was also improved in
Cpt1bm/ mice during an insulin tolerance test (ITT). Similar to
the GTT, these improvements in insulin sensitivity were negated
in DKO mice compared to Cpt1bm/ mice (Figure 6B). Consis-
tent with this, basal phosphorylation of Akt (Ser473) in skeletal
muscle of DKO mice was significantly higher compared to
Cpt1bm/muscle, whereas it was significantly lower compared
to Fgf21/ muscle and was indifferent compared to control
mice muscle (Figure 6C). However, insulin-stimulated phosphor-
ylation of Akt (Ser473) in muscle of DKO was comparable to
levels in control and Cpt1bm/ muscle (Figure 6D). Phosphory-
lation of Akt1 (Ser473) at baseline was not different among all ge-notypes (Figure 6E). However, Akt1 phosphorylation in response
to insulin in muscle of DKO mice was similar to Cpt1bm/mus-
cle and was significantly increased compared to control mice
muscle (Figure 6F), indicating again that Fgf21 is downstream
of Akt1 signaling inCpt1b-deficientmuscle (Figure 2H). Reduced
phosphorylation of Akt2 (Ser474) at baseline in skeletal muscle of
Cpt1bm/mice was reversed in muscle from DKO mice so that
it was comparable to that from control mice (Figure 6G), whereas
Akt2 phosphorylation in response to insulin was comparable
among all genotypes (Figure 6H). These data reinforce a possible
feedback inhibition of mTORC1 by FGF21, through which FGF21
contributes to enhanced basal insulin sensitivity in Cpt1bm/
mice (Figure 2H).
Muscle-Derived FGF21 Promotes Browning of Inguinal
WAT in Cpt1bm/ Mice
Because serum FGF21 levels were significantly higher in both
fed and fasted states in Cpt1bm/ mice (Figure 1A), we exam-
ined FGF21 signaling in other metabolic tissues in Cpt1bm/Cell Reports 15, 1686–1699, May 24, 2016 1693
mice. Gene expression of Klb and Fgfr1b was significantly
increased in WAT of Cpt1bm/ mice compared to Cpt1bfl/fl
mice without changes in Fgfr1c expression, which would facili-
tate enhanced FGF21 signaling in WAT (Figures 7A, 7B, and
S6B). Consistent with previous reports that FGF21 exerts meta-
bolic action enhancing lipolysis, fat oxidation (Coskun et al.,
2008), and accumulation of beige adipocytes in other metabolic
tissues (Fisher et al., 2012; Keipert et al., 2014), expression of
Pnpla2, Hadha, and Cs genes was significantly upregulated in
WAT of Cpt1bm/ mice compared to control mice, without
affecting liver expression (Figures 7C–7E and S6C). Collectively,
these data are consistent with elevated lipolysis and lipid oxida-
tion in WAT depots but not in liver of Cpt1bm/ mice (Figures
7C–7E and S6C). This seems to be at least partially mediated
via FGF21, because DKO mice exhibit significantly attenuated
gene expression of the lipolytic marker Pnpla2 (Atgl) in WAT of
DKO mice compared to Cpt1bm/ mice (Figure 7C), as well as
reduced expression of fat oxidation markers Hadha and Cs in
inguinal WAT (iWAT) of DKO mice (Figures 7D and 7E). Alterna-
tively, Hadha and Cs gene expression was similar in epididymal
WAT (eWAT) of DKOmice compared toCpt1bm/mice (Figures
7D and 7E).
In addition, expression of brown adipocyte markers such as
Ucp1 and Cidea was significantly increased in iWAT, but not in
eWAT, of Cpt1bm/ mice compared to control mice (Figures
7F and S6D). Expression of Ucp1 and Cidea was entirely
attenuated in iWAT of Fgf21/ and DKO mice compared to
Cpt1bm/mice (Figure 7F). Given the reversal of FAO enzymes
and Ucp1 and Cidea expression by loss of FGF21 in DKO mice,
increased fat mass might be expected. However, neither fat
mass byNMR (Figure 5B) nor individual fat padweight (Figure 5D)
were different between DKO mice and Cpt1bm/mice. In addi-
tion, there is an obvious decrease in adipocyte size inCpt1bm/
mice compared to control mice that is not changed by the loss of
FGF21 (Figure 7G).
Effects on Liver, Pancreas, IGF-1, and Adiponectin in
Cpt1bm/ Mice
The pancreas and liver are both known producers and targets of
FGF21 (Fon Tacer et al., 2010). In Figure 1B, we reported no in-
crease in FGF21 expression in liver ofCpt1bm/mice. Likewise,
the expression of Klb, Fgfr4, and Fgfr1c in liver of Cpt1bm/
mice was unaltered compared to Cpt1bfl/fl mice (Figures S6E
and S6F). Expression of Fgfr1b was significantly increased in
liver of Cpt1bm/ mice. However, the expression level was
negligible compared to expression of other Fgf receptors in liver
(Figure S6F). In addition, gene expression of Fgf21 and of Klb
and Fgf receptors in pancreas was comparable between
Cpt1bm/ and Cpt1bfl/fl mice (Figures S6G and S6H).
In a transgenic animal model, it has been shown that FGF21-
overexpressing mice have significantly lower levels of IGF-1
compared to wild-type mice (Inagaki et al., 2008). Serum levels
of IGF-1 were significantly lower in Cpt1bm/ mice (n = 52–59)
(Figure S7A). In a smaller cohort, IGF-1 was significantly lower
in Cpt1bm/ mice and DKO mice compared to control and
Fgf21/ mice (Figure S7B). These data are consistent with
decreased body length in Cpt1bm/ and DKO mice (Figure 5E),
but they do not suggest that reduced IGF-1 is driven by1694 Cell Reports 15, 1686–1699, May 24, 2016increased circulating FGF21 in Cpt1bm/ mice. Though the
metabolic effect of FGF21 has been shown to be dependent
upon adiponectin (Holland et al., 2013), the expression of adipo-
nectin receptors, Adipor1 and Adipor2, was not different in skel-
etal muscle betweenCpt1bm/ andCpt1bfl/fl mice (Figures S6C
and S6D). Serum levels of total and highmolecular weight adipo-
nectin were also similar between Cpt1bm/ and Cpt1bfl/fl mice
(Figures S6E and S6F). This is consistent with a paper (Kolumam
et al., 2015) demonstrating FGF21 mimetic antibody has meta-
bolic effects in adiponectin-knockout mice.
DISCUSSION
Previously, we showed that AMPK/PGC1a activated by energy
deprivation orchestrates compensatory increases in mitochon-
drial biogenesis, mitochondrial oxidative capacity, fat oxidation
by peroxisomes, and usage of amino acids as energy sources
in Cpt1bm/ muscle (Wicks et al., 2015). Here we show that
AMPK, through activation of the TSC complex, (1) activates
mTORC2-Akt1-FGF21, leading to an increase in Glut1, and (2)
inactivates mTORC1-S6K-IRS-1 serine phosphorylation. Both
stimulate glucose uptake at low insulin levels.
The induction of FGF21 in response to impaired mitochondrial
FAO in skeletal muscle is a part of several compensatory adap-
tations designed to maintain energy supply to muscle in
Cpt1bm/ mice. While liver is considered the major organ for
the upregulation and secretion of FGF21 in an energy- or
nutrient-deficient state, muscle has also been shown to secrete
FGF21. Energy deficit caused by respiratory chain deficiencies
leads to mitochondrial myopathy and increased FGF21 produc-
tion in mice and humans (Suomalainen et al., 2011; Tyynismaa
et al., 2010). In another model of mitochondrial inefficiency,
muscle-specific overexpression of UCP-1 causes FGF21 upre-
gulation in skeletal muscle (Keipert et al., 2014; Ost et al.,
2015). Dysregulation of lipid delivery to mitochondria by either
overexpression of perilipin 5 (Harris et al., 2015) or deletion of
the lipase ATGL (Brahma et al., 2014), leads to FGF21 induction
in skeletal muscle or heart, respectively. Taken together with our
data, these results suggest that many pathophysiological condi-
tions (disorders of lipid uptake and transport, lipid droplet forma-
tion and lipolysis, any defect in the carnitine shuttle system,
disorders of mitochondrial FAO, and mitochondrial dysfunction)
stimulate FGF21 production in muscle.
All preceding models represent rather severe conditions that
identified specific pathways for FGF21 regulation in muscle.
While still not physiological, one study demonstrated that after
a prolonged 3–4 hr hyperinsulinemic-euglycemic clamp, both
skeletal muscle FGF21 mRNA and circulating FGF21 were
increased (Hojman et al., 2009). The hyperinsulinemic-euglyce-
mic clamp procedure can be considered a period of suppression
of FAO. In the present study, we demonstrate that there is min-
imal FGF21 expression in murine or human primary myotubes
and that incubation of either murine or human primary myotubes
with a palmitate-oleate mixture or the CPT1 inhibitor etomoxir
alone has no effect on FGF21 mRNA. However, the combination
of fatty acids and etomoxir increases FGF21 expression nearly
10-fold (Figures 3A–3C).We also demonstrate that FGF21 induc-
tion is blunted in differentiated myotubes from obese-diabetic
Figure 7. Muscle-Derived FGF21 Enhances Browning in WAT in Cpt1bm/ Mice
(A and B) Gene expression of Klb (A) and Fgfr1b (B) in eWAT and iWAT (n = 5–7 per group).
(C–F) qRT-PCR analysis of expression of a lipolytic gene (Pnpla2; C), mitochondrial FAO genes (Hadha andCs; D and E), and beige adipocytemarker genes (Ucp1
and Cidea; F) in WAT.
(G) H&E staining of iWAT. Scale bar represents 100 mm.
(H) Summary of the phenotype in Cpt1bm/ mice compared to control mice and the reverse phenotype in DKO mice. Tissue from control (Fgf21+/+ Cpt1bfl/fl),
Cpt1bm/ (Fgf21+/+ Cpt1bm/), Fgf21/ (Fgf21/ Cpt1bfl/fl), and DKO (Fgf21/ Cpt1bm/) mice was used for all qRT-PCR analysis (n = 5–7 per group).
All data are presented as mean ± SEM. (A and B) *p < 0.05 and **p < 0.005 and higher significance. (C–F) *p < 0.05 significance compared to control mice, #p <
0.05 significance compared to Fgf21/ mice, and &p < 0.05 significance compared to Cpt1bm/ mice.
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subjects. Moreover, we observe decreased mitochondrial FAO
induces FGF21 in otherwise ‘‘healthy’’ myotubes. We also
demonstrate that the regulation of FGF21 production appears
to be mediated through an AMPK-mTOR-Akt1 axis (Figures
3A–3C). This is in agreement with a transgenic mouse model,
in which overexpression of Akt1 induces FGF21 secretion from
muscle (Izumiya et al., 2008). Two previous studies report bene-
ficial effects of FGF21 treatment on human myotubes by
increasing glucose uptake (Mashili et al., 2011) and suppressing
necrosis factor kB (Lee et al., 2012). We further show that FGF21
has beneficial effects in human myotubes. FGF21 was able to
repress mTORC1, leading to subsequent repression of IRS1
phosphorylation at Ser636/639 and improved downstream insu-
lin signaling in the presence of FA.
Numerous studies demonstrate that the induction of FGF21
requires an ATF4-dependent mechanism (De Sousa-Coelho
et al., 2012; Kim et al., 2013a; Kim et al., 2013b; Ost et al.,
2015; Tyynismaa et al., 2010). We were surprised to see no
changes in Atf4 mRNA or protein levels in Cpt1bm/ mice. In
addition, markers for oxidative stress (Nrf2), hypoxia (Hif1a),
and ER stress (unspliced Xbp1u and spliced Xbp1s, Ddit3)
were not elevated in Cpt1bm/ muscle (Figure 4). In addition,
a comprehensive global expression analysis demonstrated that
ER stress, autophagy, and mitophagy pathways are not signifi-
cantly different between Cpt1bm/ and control mice (Figures
S3–S5). Despite the accumulation of total lipid and lipotoxic in-
termediates, the skeletal muscle fromCpt1bm/mice has char-
acteristics similar to that from trained athletes (Goodpaster et al.,
2001), including increased glucose and lipid uptake, large lipid
droplets, increased mitochondrial biogenesis, and increased
mitochondrial oxidative capacity, although Cpt1bm/ mice are
hypoactive (Wicks et al., 2015).
When we investigated the role of muscle-derived FGF21 in the
obesity-resistant phenotype in Cpt1bm/ mice at the whole-
body level (see Figure 7H for summary), DKO mice showed a
modest attenuation in the body weight reduction observed in
Cpt1bm/mice. However, the increase in body weight between
Cpt1bm/ and DKO mice was entirely accounted for by an in-
crease in FFM in DKO mice. The decreased fat mass and body
length observed in Cpt1bm/ mice was not corrected by the
absence of FGF21. Examination of individual tissues again
shows that the reduced fat mass in Cpt1bm/ mice is not
increased in DKO mice. Likewise, the mass of major organs,
such as liver, heart, and kidney, is still reduced in DKO mice.
We did observe an increase in skeletal muscle mass in both
Fgf21/ and DKO mice, which is probably responsible for the
increased FFM. The reduced spontaneous activity observed in
Cpt1bm/mice is normalized in DKOmice. The increased activ-
ity may be supported by the increased muscle mass rather than
the known effects of FGF21 on torpor and circadian rhythms
(Bookout et al., 2013), because activity in Fgf21/ mice is not
greater than that in control mice (Figure 5).
The improved glucose uptake during a GTT was partially
blunted in DKO mice, and the marginal decrease in blood
glucose during an ITT was returned to control levels in DKO
mice. At the muscle level, the reduced phosphorylation of Akt2
at baseline in Cpt1bm/ muscle was substantially reversed in
muscle of DKO mice, indicating that FGF21 contributes largely1696 Cell Reports 15, 1686–1699, May 24, 2016to the improvement in basal insulin sensitivity inCpt1bm/mus-
cle. When we investigated the role of FGF21 in the increased
oxidative capacity of Cpt1bm/ muscle, we found that DKO
mice showed further increases in peroxisomal fat, carbohydrate,
and amino acid oxidation. A potential explanation is that benefi-
cial effects of FGF21 on glucose uptake are gone in DKO mice
and that the muscle is further compensating to increase oxida-
tive capacity.
FGF21 has been reported to ameliorate diet-induced obesity
and insulin resistance by increasing lipolysis and b-oxidation
(Coskun et al., 2008; Inagaki et al., 2007; Kharitonenkov et al.,
2005) We detected elevated markers of mitochondrial number,
lipolysis, b-oxidation, and adipocyte browning in WAT of
Cpt1bm/ mice. Moreover, expression of browning markers
was reversed in iWAT of DKO mice, reaching levels similar to
those in control mice. However, the reversal of browningmarkers
has no effect on fat mass as measured by NMR, mass of individ-
ual fat depots, or adipocyte histology, suggesting the level of
browning observed in Cpt1bm/ mice is not high enough to
increase whole-body energy expenditure. The lack of an effect
of FGF21 on adiposity was also observed in the transgenic
mice overexpressing UCP-1 in skeletal muscle (Ost et al., 2015).
In summary, the combination of elevated fatty acids and
CPT1b inhibition increases FGF21 production in skeletal muscle
via an AMPK-mTor-Akt1 pathway. This regulation does not
involve induction of the ER stress pathway, which has been re-
ported to be a primary mediator of FGF21 induction in skeletal
muscle under pathological conditions. Results from the present
study indicate that production of FGF21 in skeletal muscle of
Cpt1bm/ mice improves metabolic health, because FGF21
appears to act in a paracrine manner in muscle to improve
glucose uptake in these mice. While circulating FGF21 does
produce browning in adipose tissue, FGF21 does not drive the
obesity-resistant phenotype observed in Cpt1bm/ mice.
Further studies are needed to evaluate FGF21-independent
pathways in Cpt1bm/ mice that would provide new insights
on resistance to diet-induced obesity. Altogether, our findings
suggest that pharmacologically targeted CPT1b inhibition spe-
cifically in skeletal muscle could trigger favorable adaptive re-
sponses, resulting in improved glucose uptake and reduced fat
mass, and that the improvements in glucose homeostasis are
partially driven by muscle-specific upregulation of FGF21.
EXPERIMENTAL PROCEDURES
Animal Studies
Animal studies were conducted at Pennington Biomedical Research Center’s
American Association for Laboratory Animal Care (AALAC)-approved facility
on a standard breeder chow diet, composed of 20% protein, 25% fat, and
55%carbohydrate (PurinaRodentChowno. 5015, PurinaMills). All experiments
were in compliance with the NIH Guide for the Care and Use of Laboratory An-
imals and approved by the Institutional Animal Care and Use Committee. All
mice used in the experiments were 3–4 months old unless specified otherwise.
Animal Procedures
Serum and plasma collections were performed by submandibular bleed. GTTs
were performed following a 4-hr fast by intraperitoneal (i.p.) injection of 10%
D-glucose (0.68 g/kg body weight). ITTs were done in the fed state using an
i.p. dose of 0.04 U/kg body weight. For insulin signaling studies, mice were
fasted overnight and then given an i.p. injection of insulin (1.0 U/kg body
weight); tissues were collected 10 min later. Indirect calorimetry was done in a
16-chamber Oxymax system (Columbus Instruments) (Wicks et al., 2015).
ELISA
ELISA kits were used for measurement of FGF21 (BioVendor) in serum and su-
pernatant of mouse primary muscle cell culture, IGF-1 (Abcam) in serum, and
total and high molecular weight adiponectin (ALPCO Diagnostics) in plasma.
qRT-PCR
qRT-PCRwas conducted using DDCT assay as described previously (Vandan-
magsar et al., 2011). Mouse and human cyclophilin B were used as a house-
keeping-gene control for normalization of gene expression. Primer details
are provided in Table S1.
Western Blot Analysis
Protein homogenates were prepared from muscle tissue in cell lysis buffer
(EMD Millipore). Immunoblot analyses were performed using standard proce-
dures. See Supplemental Experimental Procedures for details.
Mouse Primary Muscle Cell Culture
Cultures were established from mixed hindlimb muscle from 1- and 3- to
5-month-old Cpt1bm/ and Cpt1bfl/fl littermates (Rando and Blau, 1994).
See Supplemental Experimental Procedures for details.
Human Skeletal Muscle Myoblast Culture
Cryopreserved human skeletal muscle myoblasts (HSMMs) from four normal-
lean (BMI, 19.8 ± 0.7), and four diabetic-obese (BMI, 32.6 ± 4.2) subjects at
passage 2 were purchased from Lonza and cultured as previously described
(Vandanmagsar et al., 2014). See Supplemental Experimental Procedures
for details.
Multiplex Mapmate Signaling Assay
Harvested muscle tissue frommouse was snap-frozen in liquid nitrogen. Then,
entire muscle tissue was powdered in liquid nitrogen and used for protein
lysate preparation in cell signaling lysis buffer (Millipore). Differentiated and
treated human myotubes were harvested in cell signaling lysis buffer (Milli-
pore). See Supplemental Experimental Procedures for details.
Glucose Uptake
Glucose uptake was measured in mouse primary myotubes as described in
Noland et al. (2009). See Supplemental Experimental Procedures for details.
Substrate Oxidation Assays
Gastrocnemius muscle homogenates were prepared as previously described
(Noland et al., 2007). Peroxisomal FAO was measured from [1-14C]lignoceric
acid (20 mM), PDH activity and pyruvate oxidation were measured from
[1-14C]puruvate and [3-14C]puruvate, and leucine oxidation was measured
by capturing 14CO2 from [U-
14C]leucine (100 mM) as previously described
(Wicks et al., 2015).
Statistical Analysis
Data are expressed as mean ± SEM. GraphPad Prism 5 software was used for
ANOVA or repeated-measures ANOVA and Bonferroni post-tests or two-tailed
Student’s t test. p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.04.057.
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